Back
Beam Therapeutics Quote, Financials, Valuation and Earnings
Sponsored
BEAM
Sponsored
Hint at where the next big move in the market will be this month
Spot the next big move with this free book from a hedge fund manager
Sell
32
BEAM
Beam Therapeutics
Last Price:
26.02
Seasonality Move:
33.43%
7 Day Trial
ALL ACCESS PASS
$
7
How this hedge fund manager trades weekly options
Claim your free training on trading weekly optionsBeam Therapeutics Price Quote
$26.02
+0.51 (+2%)
(Updated: September 19, 2024 at 6:55 PM ET)
Beam Therapeutics Key Stats
Sell
32
Beam Therapeutics (BEAM)
is a Sell
Day range:
$24.96 - $27.04
52-week range:
$16.95 - $49.50
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
5.86
P/B ratio:
2.46%
Volume:
784.8K
Avg. volume:
675.2K
1-year change:
4.94%
Market cap:
$2.1B
Revenue:
$377.7M
EPS:
$-1.81
How Much Does Beam Therapeutics Make?
-
How Much Are Beam Therapeutics's Sales Annually?
BEAM Revenues are $377.7M -
How Much Profit Does Beam Therapeutics's Make A Year?
BEAM net income is -$132.5M
Is Beam Therapeutics Growing As A Company?
-
What Is Beam Therapeutics's Growth Rate Quarterly?
Quarterly YoY revenue growth is -0.41% -
What Is Beam Therapeutics's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0%
Beam Therapeutics Stock Price Performance
-
Did Beam Therapeutics Stock Go Up Last Month?
Beam Therapeutics share price went up by 4.42% last month -
Did BEAM's Share Price Rise Over The Last Year?
BEAM share price rose by 4.94% over the past 1 year
What Is Beam Therapeutics 52-Week High & Low?
-
What Is Beam Therapeutics’s 52-Week High Share Price?
Beam Therapeutics has traded as high as $49.50 over the past 52 weeks -
What Is Beam Therapeutics’s 52-Week Low Share Price?
Beam Therapeutics has traded as low as $16.95 over the past 52 weeks
Beam Therapeutics Price To Free Cash Flow
Data Unavailable
Is It Risky To Buy Beam Therapeutics?
-
How Much Debt Does Beam Therapeutics Have?
Total long term debt quarterly is $0 -
How Much Cash Does Beam Therapeutics Have?
Cash and short term investments quarterly total is $1B -
What Is Beam Therapeutics’s Book Value Per Share?
Book value per share is 10.37
Is Beam Therapeutics Cash Flow Positive?
-
What Is BEAM Cash Flow From Operations?
Cash flow from operations (TTM) is -$137.5M -
What Is Beam Therapeutics’s Cash Flow From Financing?
Cash flow from financing (TTM) is $73.5M -
What Is Beam Therapeutics’s Cash Flow From Investing?
Cash flow from investing (TTM) is $121.9M
Beam Therapeutics Return On Invested Capital
-
Is Management Doing A Good Job?
BEAM return on invested capital is -16.48% -
What Is Beam Therapeutics Return On Assets?
ROA measures how assets are converting to revenues and is -10.63% -
What Is BEAM Return On Equity?
ROE is a measure of profitability and is -16.48%
Beam Therapeutics Earnings Date & Stock Price
-
What Is Beam Therapeutics's Stock Price Today?
A single share of BEAM can be purchased today for 25.51 -
What Is Beam Therapeutics’s Stock Symbol?
Beam Therapeutics trades on the nasdaq under the ticker symbol: BEAM -
When Is Beam Therapeutics’s Next Earnings Date?
The next quarterly earnings date for Beam Therapeutics is scheduled on November 8, 2024 -
When Is BEAM's next ex-dividend date?
Beam Therapeutics's next ex-dividend date is May 7, 2020 -
How To Buy Beam Therapeutics Stock?
You can buy Beam Therapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Beam Therapeutics Competitors
-
Who Are Beam Therapeutics's Competitors?
Below is a list of companies who compete with Beam Therapeutics or are related in some way:
Beam Therapeutics Dividend Yield
-
What Is BEAM Dividend Yield?
Beam Therapeutics’s dividend yield currently is 0% -
What Is Beam Therapeutics’s Payout Ratio?
Beam Therapeutics’s payout ratio is 0% -
When Did Beam Therapeutics Last Pay A Dividend?
The latest dividend pay date is September 20, 2024 -
What Is Beam Therapeutics’s Dividend Per Share?
Beam Therapeutics pays a dividend of $0.00 per share
Beam Therapeutics Analyst Estimates
YoY Growth | Past Surprise | |
---|---|---|
EPS: | 0% | 0.73% |
Revenue: | -41.48% | -9.77% |
Analyst Recommendations
Buy Recommendations: | 6 |
---|---|
Hold Recommendations: | 7 |
Sell Recommendations: | 0 |
Price Target: | 50.36 |
Upside from Last Price: | 97.4% |